ControlHF in the news.

A new study out of UCSF Medical Center found that patients enrolled in ControlHF's remote monitoring program were nearly half as likely to be readmitted within 90 days of discharge. Cardiologists are calling it one of the most significant clinical results in digital health in a decade.

ControlHF connects patients with their care teams through daily weight and symptom check-ins, alerting doctors before a crisis unfolds. Patients who used the app for six months reported feeling more in control of their condition than at any point since their diagnosis.

A prospective cohort study of 1,240 heart failure patients using ControlHF's remote monitoring protocol showed a 31% reduction in six-month mortality risk compared to usual care. The study authors attribute the results to earlier clinical intervention driven by algorithmic alert thresholds.

ControlHF raised $42 million in Series B funding this fall, with investors betting that its clinical-grade monitoring platform can expand beyond heart failure into other chronic conditions. The company's reimbursement model — billing through Medicare's RPM codes — gives it a durable revenue engine competitors lack.

The startup's proprietary algorithm analyzes daily biometric trends — weight, heart rate, blood pressure, and symptom scores — to predict fluid overload before patients notice any changes. Early adopter clinics report that the 72-hour lead time is enough to intervene with medication adjustments and avoid hospitalization entirely.

Unlike most digital health tools that promise to replace physician judgment, ControlHF is built to amplify it. The platform's alert system routes directly into cardiologist workflows — EHR-integrated, actionable, and designed by a team of practicing clinicians who refused to ship a product they wouldn't use themselves.